RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a 1-for-8 reverse stock split effective at 11:59 pm ET on June 16, 2025. Post-split, the company's common stock will trade under the symbol "RAPT" with a new CUSIP number starting June 17, 2025. This adjustment reduces the outstanding shares from approximately 132.3 million to 16.5 million, without altering the total number of authorized shares. The reverse split affects all shareholders equally and maintains their relative equity stakes, with adjustments made for fractional shares through cash payments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。